What is InoCardia?
InoCardia operates at the intersection of biotechnology and artificial intelligence, specializing in the delivery of superior, predictive cardiac contractility data. The company's core competency lies in its ability to manipulate pre- and after-load conditions while directly measuring microscopic changes in contraction force. This technical capability is further enhanced by the development of the cardiac contractome AI concept, a breakthrough initiative supported by EIT Digital. By miniaturizing its Work Loop platform through successful collaborations with NC3R and InnovateUK, InoCardia provides pharmaceutical researchers with a high-fidelity suite of data that is essential for identifying potential cardiotoxicity early in the development cycle. This unique value proposition positions the company as a critical partner for global drug discovery efforts.
How much funding has InoCardia raised?
InoCardia has raised a total of $452K across 1 funding round:
Private Equity
$452K
Private Equity (2015): $452K with participation from Mercia Fund Management
Key Investors in InoCardia
Mercia Fund Management
Mercia Asset Management PLC is a regionally focused private capital asset manager that provides venture capital, business loans, and private equity to UK businesses. The firm specializes in accelerating growth and innovation across a diverse portfolio of companies through a network of regional offices.
What's next for InoCardia?
With the recent influx of capital, InoCardia is poised to accelerate the commercialization of its cardiac contractome AI platform. The strategic roadmap involves deepening its integration into global drug discovery workflows, where the demand for predictive, high-throughput cardiac screening is at an all-time high. By scaling its operational capacity, the company aims to transition from a research-focused entity to a standard-setting provider of cardiac safety data. Future growth will likely be driven by expanding its intellectual property portfolio and forging deeper partnerships with major pharmaceutical firms seeking to optimize their R&D efficiency. The company's trajectory suggests a move toward broader market adoption, leveraging its unique technological edge to mitigate the high failure rates typically associated with cardiac-related drug development.
See full InoCardia company page
